<i>CYP3A5</i> Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients

<i>CYP3A5</i> Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients

Tacrolimus has been used to induce remission in patients with steroid-refractory ulcerative colitis. It poses a problem of large individual differences in dosage necessary to attain target blood concentration and, often, this leads to drug inefficacy. We examined the difference in mRNA expression le...

Full description

Bibliographic Details
Main Authors: Yuki Yamamoto, Hiroshi Nakase, Minoru Matsuura, Shihoko Maruyama, Satohiro Masuda
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:International Journal of Molecular Sciences
Subjects:
mucosal concentration
clinical activity index
multidrug resistance 1
polymorphism
inflammatory bowel disease
Online Access:https://www.mdpi.com/1422-0067/21/12/4347

Internet

https://www.mdpi.com/1422-0067/21/12/4347

Similar Items